Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Impact of BRAF mutation on efficacy of ipilimumab/nivolumab versus single-agent PD-1 inhibitor (nivolumab or pembrolizumab) in patients with metastatic or unresectable melanoma: A single centre, retrospecctive study

Next Previous
Trial Profile

Impact of BRAF mutation on efficacy of ipilimumab/nivolumab versus single-agent PD-1 inhibitor (nivolumab or pembrolizumab) in patients with metastatic or unresectable melanoma: A single centre, retrospecctive study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Jun 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Therapeutic Use

Most Recent Events

  • 09 Jun 2020 New trial record
  • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top